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VlincRNAs controlled by retroviral elements are a
hallmark of pluripotency and cancer
Georges St Laurent1,2*, Dmitry Shtokalo1,3, Biao Dong4, Michael R Tackett1, Xiaoxuan Fan4, Sandra Lazorthes5,6,
Estelle Nicolas5,6, Nianli Sang7, Timothy J Triche8, Timothy A McCaffrey9, Weidong Xiao4* and Philipp Kapranov1*
Abstract
Background: The function of the non-coding portion of the human genome remains one of the most important
questions of our time. Its vast complexity is exemplified by the recent identification of an unusual and notable
component of the transcriptome - very long intergenic non-coding RNAs, termed vlincRNAs.
Results: Here we identify 2,147 vlincRNAs covering 10 percent of our genome. We show they are present not only
in cancerous cells, but also in primary cells and normal human tissues, and are controlled by canonical promoters.
Furthermore, vlincRNA promoters frequently originate from within endogenous retroviral sequences. Strikingly, the
number of vlincRNAs expressed from endogenous retroviral promoters strongly correlates with pluripotency or the
degree of malignant transformation. These results suggest a previously unknown connection between the
pluripotent state and cancer via retroviral repeat-driven expression of vlincRNAs. Finally, we show that vlincRNAs
can be syntenically conserved in humans and mouse and their depletion using RNAi can cause apoptosis in
cancerous cells.
Conclusions: These intriguing observations suggest that vlincRNAs could create a framework that combines many
existing short ESTs and lincRNAs into a landscape of very long transcripts functioning in the regulation of gene
expression in the nucleus. Certain types of vlincRNAs participate at specific stages of normal development and,
based on analysis of a limited set of cancerous and primary cell lines, they appear to be co-opted by cancer-
associated transcriptional programs. This provides additional understanding of transcriptome regulation during the
malignant state, and could lead to additional targets and options for its reversal.
Keywords: vlincRNA, LTR, macroRNA, cancer, embryonic stem cell, non-coding RNA, intelligent scaffold, single
molecule sequencing, RNAseq
Background
Over the past 10+ years, efforts to understand the
complexity of the human transcriptome have employed a
number of independent technologies to discover and char-
acterize the extent of transcription from non-coding
regions [1-4]. While little doubt remains about the exis-
tence of this “dark matter” RNA, as highlighted by the
recent ENCODE papers [5,6], its function and biological
significance continues to generate controversy [3,7-11].
Much of the problem stems from an insufficient theoretical
basis to classify and categorize the dark matter transcripts,
and thus they can appear as transcriptional ‘noise’ made by
the cell. Another part of the problem arises from our gen-
ome’s large number of repetitive sequences of retroviral
origin. The presence of so many of these poorly conserved
elements is often mentioned to support the notion that the
non-coding portion of the genome has little function.
Recently, by profiling total RNA depleted of ribosomal
RNAswith single-molecule sequencing (SMS), we revealed
an intriguing phenomenon: the presence of very long
(50 to ~700 kb) transcribed regions of human non-coding
intergenic genomic space [12]. These regions, dubbed
vlincRNAs for very long intergenic non-coding regions,
were found in tumors, and showed highly cell-type specific
expression patterns. Unlike many non-coding RNAs with
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low levels of expression, RNAs produced from these novel
vlincRNA regions were relatively abundant by mass in the
cell [12]. The length of these regions emerged as a promi-
nent feature, which, together with an absence of any
obvious coding potential, made them similar to macro-
RNAs such as Airn or KCNQ1OT1, yet distinct from the
previously identified long-intergenic ncRNAs (lincs) [13].
MacroRNAs are very long, un-spliced RNAs driven by
canonical RNA Pol II promoters that function in the
maintenance of imprinting in normal tissues [14,15]. How-
ever, only a few characterized examples of macroRNAs
exist, leading to the belief that they occur only rarely in
the human genome [14,15].
Here we show that vlincRNAs encode functional
RNAs whose combined properties parallel those of the
macroRNAs except that they criss-cross our genome in
very large numbers. Regulated by relatively few dedi-
cated promoters, these very large transcripts account
for much of the dark matter transcription in the cell.
Strikingly, we show that retroviral repeats, the quintes-
sential dark matter of the genome, tend to specifically
associate with tissue-specific vlincRNAs. This associa-
tion occurs in both transformed and pluripotent cells,
pointing to yet another un-anticipated link between
pluripotency and malignancy.
Results
VlincRNAs exist in very large numbers in a variety of
cancerous and normal cell types
In this work, we identify and characterize over 2000
vlincRNAs found in a number of published and unpub-
lished datasets (Table 1). We generated a Single Molecule
Sequencing (SMS) RNA-seq dataset from human blood
(Materials and Methods) in order to profile a human
primary tissue containing diverse cell types, free of cell
culture or other in-vitro artifacts. In addition, we used the
ENCODE/CSHL long nuclear polyA-RNAseq dataset [5,6]
consisting of several cell lines of cancerous or primary ori-
gin (Materials and Methods). First, we determined the
reproducibility of our original vlincRNA observations [12]
by verifying their detection on different sequencing plat-
forms, by different research groups, and in different RNA
isolations from the same cell line. Of the 60 vlincRNAs
previously identified by us on the Helicos SMS platform as
specific to the K562 human cell line [12] (see below), 56
were expressed in the ENCODE K562 long RNAseq data-
set generated with the Illumina platform. This result con-
firmed that vlincRNAs are bona fide RNAs present in a
cell. Overall, 341 of the original 580 tumor vlincRNAs [12]
(Table 1) overlap ENCODE vlincRNAs identified from
mostly different cell lines, using a different sequencing
platform (p-value 1.54 × 10-45).
VlincRNAs were found in all cell lines tested, includ-
ing non-cancerous cell lines and tissues (Table 1).
Embryonic stem cell line H1-hEsc expressed 469 such
regions, while non-cancerous normal human epidermal
keratinocyte line (NHEK) and normal human umbilical
vein endothelial cells (HUVEC) expressed 248 and 340
vlincRNAs, respectively (Table 1; Additional File 1,
Table S1). A complex normal human tissue, blood,
revealed expression of 613 vlincRNAs, of which 331
(p-value 2.03 × 10-49) overlap ENCODE vlincRNAs. Of
2,285 vlincRNAs found in cancerous or immortalized
cells/tissues, 1,088 (47.7%) occurred in the non-cancerous
cell lines or blood. While cancerous cells have highly-
rearranged genomes and, in theory, could produce
non-functional vlincRNA transcripts that reflect those
re-arrangements, this argument cannot be made about the
Table 1 Total number of vlincRNAs and overlap with All promoters in different cell lines and tissues
Source Cell line/
Tissue
Cell Type Number of
vlincRNAs
VlincRNAs Overlapping
with All Promoters
Overlap Expected
by Chance
Fold over
chance
p-value
Kapranov et al [12] K562 + Ewing
Sarcomas
Malignant 580 336* 131.7 2.5 2.4E-74
This work Blood Normal
Tissue
613 321* 142.5 2.2 7.7E-55
ENCODE K562 Malignant 407 216** 23.2 9.3 1.3E-153
ENCODE HepG2 Malignant 501 192** 34.1 5.6 7.5E-91
ENCODE HeLaS3 Malignant 206 N/D N/D N/D N/D
ENCODE GM12878 Immortalized 591 128** 27.5 4.6 3.6E-48
ENCODE NHEK Primary 248 51** 12.1 4.2 2.28 E-18
ENCODE HUVEC Primary 340 86** 13.1 6.5 1.9E-44
ENCODE H1-hEsc Embryonic
Stem
469 205** 24.9 8.2 1.9E-130
This work Mouse Lung Normal
Tissue
225 115* 49.3 2.3 7.6E-22
* Overlap was done on combined ENCODE All promoter dataset from all 9 cell lines
** Overlap was done on the All ENCODE promoter dataset from the same cell line
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primary and embryonic stem cells. This argues that
vlincRNAs are not aberrant transcripts resulting from can-
cerous or tissue-culture conditions. An example of a
vlincRNA transcribed in both cancerous as well as
embryonic stem cells is shown in the Additional File 2,
Figure S1.
The combined number of different non-overlapping
vlincRNAs found in K562, Ewing Sarcomas, ENCODE
and human blood now totals 2,147, with the longest
vlincRNA over 1M bases in length (see Additional File 1,
Table S1). Overall, these observations tell us that the
human genome encodes thousands of very long regions
that give rise to mostly non-coding RNAs that exhibit
differential expression not only in cancerous cells, but
also in primary cell lines and normal tissues. In total,
they cover at least 10% of the genomic space and likely
much more, considering that many cell types remain to
be profiled.
VlincRNAs are controlled by normal promoters
To explore whether the promoters regulating vlincRNAs
have typical chromatin hallmarks, we utilized promoters
annotated by the ENCODE consortium in 9 cell lines,
consisting of two cancerous lines, an immortalized line, an
embryonic stem cell and four primary cell lines [5,16,17]
(Materials and Methods). The promoters segregated into 3
categories: “Active”, “Weak” and “Inactive/poised”, based
on the presence of different chromatin marks [16,17]. A
clear enrichment of promoters from the three above men-
tioned classes together ("All” promoter class), and the
“Active” class by itself, occurred around the boundaries of
the 2,147 vlincRNA regions (Figure 1A). Of the latter,
1,032 (48.06%) and 700 (32.6%) could be associated with
All and Active ENCODE promoters, respectively (p-values
of 2.82 × 10-210 and 1.0 × 10-300) (see Table 1 and Materi-
als and Methods for details).
VlincRNAs segregate into three categories: totally stan-
dalone transcripts (Figure 2), adjacent to known genes, but
transcribed bi-directionally (Figure 3 A&B), or antisense to
known genes (Figure 3 C&D). Sometimes vlincRNAs cor-
respond to spliced ESTs, but most of the RNAseq signal
maps to intronic portions of these ESTs, indicating they
probably exist in unspliced form (Figure 2A, Figure 3C).
To estimate the fraction of antisense vlincRNAs and those
transcribed bi-directionally to known genes, we examined
the 1,661 ENCODE vlincRNAs in our dataset with unam-
biguous strand assignments (Table 1). Of those, 550
(33.1%) were antisense to known genes, and 83 (5.0%)
were transcribed bi-directionally. The relatively high frac-
tion of antisense vlincRNAs was reminiscent of estimates
of 50-70+% of global antisense transcription obtained in
previous genome-wide surveys [18,19]. To exclude the
possibility that promoter enrichment comes from nearby
human genes, we created a group of 604 stand-alone
vlincRNAs from the 2,147 vlincRNAs whose boundaries
were more than 50 kb from 5’ and 3’ boundaries of anno-
tated genes. Very similar to the entire population of
vlincRNAs, we observed an enrichment of the ENCODE
promoters around the boundaries of such standalone
vlincRNAs (Figure 1B): 133 (22.0%) and 222 (36.7%) of the
604 stand-alone vlincRNAs associated with either the
Active promoters or All promoters respectively. Again,
this was highly significant with p-values of 1.85 × 10-97
and 4.61 × 10-76 .
In theory, poor alignability of short RNAseq reads due
to the presence of repetitive elements could affect the 5’
boundaries of our vlincRNAs. Using the alignability
track generated by the ENCODE project (Materials and
Methods), we generated a profile of alignability around
the +/- 10 kb window of vlincRNA ends (5’ ends for
stranded vlincRNAs and both ends for vlincRNAs with
no strand). As shown in Additional File 2, Figure S2,
reduced alignability occurred in the region 5 kb
upstream of the 5’ end for 219 out of 2147 vlincRNAs,
which could indeed cause some of them to terminate
prematurely. However, some vlincRNAs are driven by
promoters within repeats (see below) and repeats tend
to coincide with regions of poor alignability. Therefore,
the RNAseq inferred boundaries adjacent to regions of
poor alignability for some of these 219 vlincRNAs could
still result from real transcription initiation. Finally, we
can estimate that 1,928/2,147 vlincRNAs (~90%) do not
suffer from this issue.
Finally, we tested for the presence of long RNAs in
two standalone vlincRNA regions by performing a set of
overlapping long-range RTPCR reactions (Materials and
Methods). As shown by one such example of a standa-
lone, LTR-driven vlincRNA (see below) in Additional
File 2, Figure S3, the long-range RTPCR reactions can
indeed detect the presence of such RNAs. As expected,
no amplification occurred once amplicons extended
beyond the RNAseq signal in that cell line even though
the same primer set worked well on genomic DNA (see
Additional File 2, Figure S3).
Endogenous retrovirus based promoters frequently drive
tissue-specific vlincRNAs
Cell-type specificity constitutes one of the intriguing
properties of vlincRNAs, to the point where vlincRNA
expression patterns can distinguish different patients
with the same tumor type [12]. To investigate this prop-
erty, we analyzed the promoters of cell-type specific
vlincRNAs in K562, since it has annotated promoters,
ENCODE RNAseq, and SMS RNAseq data. We identi-
fied 53 K562-specific vlincRNAs and noticed a striking
enrichment for viral long terminal repeat (LTR) ele-
ments in their promoters: 62.9% of active promoters
associated with K562-specific vlincRNAs overlapped or
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Figure 1 Properties of vlincRNA-associated promoters. VlincRNAs tend to have promoters at one of their bounds (A, B) belonging to either
the Active or All category of promoters. This tendency was common to all vlincRNAs (A) or the stand alone vlincRNAs (B) defined based on
being at least 50 kb away from the nearest gene on either side. Panels A and B show the density of ENCODE promoter coverage (Y-axis) in all 9
ENCODE cell lines (see text) summed up in 1 kb bins +/-50 kb around boundary of each vlincRNA of the 2,147 vlincRNA (see Additional File 1,
Table S1). The coordinates on the X-axis refer to middle position of each bin. VlincRNAs assigned to LTR-containing promoters from any of the 9
cell lines tend to be more tissue specific (C) and have a higher RNAseq signal (D).
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fully contained an LTR repeat sequence (see Additional
File 2, Figure S4)
Repeats in general are known to drive cell type-specific
expression [20], as the K562 promoter landscape demon-
strates: 26.7% of K562 specific active promoters over-
lapped LTRs, notably higher than that of all Active
promoters (7.7%) (Table 2). However, as mentioned
above, the vlincRNA associated fraction was far higher at
62.9%. For comparison, the same fraction associated with
K562-specific known genes was only 25.4% (see Addi-
tional File 2, Figure S4). Reciprocally, 75.6% of the K562-
specific vlincRNAs could be assigned to at least one
K562-specific Active promoter with an LTR. The corre-
sponding fraction for K562-specific Known Genes
was ~3x lower, 26.3%. Thus, LTR-containing promoters
strongly associate with tissue-specific vlincRNAs, more
so than all tissue-specific Active promoters or tissue-
specific transcripts encoding proteins (see Additional
File 2, Figure S4).
To further validate the contribution of LTRs in
vlincRNA promoters, we used the ENCODE Transcrip-
tion Factor Binding Sites [5,21] (Materials and Methods).
Overall, 88.2% of the vlincRNA LTR promoters bind
RNA pol II and other transcription factors directly to the
Figure 2 Examples of two stand-alone K562-specific vlincRNAs that are distal from annotations. VlincRNAs supported by EST evidence (A & B)
and with no EST evidence (C & D) are shown. Zoom-in on the corresponding promoter regions marked by arrows in A& C are shown in the panels B
& D. The original 580 vlincRNAs[12] (black, non-strand specific) and the ENCODE vlincRNAs (green, strand-specific) are shown. The vlincRNA
designations (vlinc_500 and vlinc_21) refer to Supplementary Table S3 of Kapranov et al [12]. Vlinc_500 (A & B) represents an example of a novel
region of ~350 kb whose left bound corresponds fairly well to a cluster of spliced ESTs that share the same 5’ ends. Consistent with the K562-specific
nature of this region, 9 out of 13 of these ESTs have been isolated from a chronic myelogenous leukemia (CML), the same cancer type as K562, with
one of the 9 ESTs spanning almost the entire length of vlincRNA (A). The common 5’ end of these ESTs falls within the annotated K562-specific
promoter that has within its core an LTR sequence (B). Most of the RNAseq signal was in the intronic regions of these ESTs, consistent with the overall
observation that majority of the “dark matter” RNA signal is intronic [12]. Unlike vlinc_500 which is supported by the EST evidence, Vlinc_21 (~121 kb;
panels C & D) is located within a totally un-annotated region of chromosome 1 with no spliced EST, ~1.4 Mb from the closest UCSC gene annotation.
It also has an LTR repeat at its core (D). RNAseq data shows density of informative reads normalized by 10M informative reads. The Y-axis of the
alignability track (Materials and Methods) is on the scale of 0 to 1. Coordinates: hg18.
St Laurent et al. Genome Biology 2013, 14:R73
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LTR sequences, as exemplified in Figures 2 and 3.
Notably, the K562-specific vlincRNAs and the associated
LTR-containing promoters were found by two very dif-
ferent means (RNAseq and ChIP-seq) performed by two
different groups on totally different batches of K562 cells.
This consistency argues for a tight control over cell type-
specific activation of these LTR-based promoters and
against spurious transcriptional noise. To show that
Figure 3 Examples of two stand-alone K562-specific vlincRNAs that are adjacent (A & B) or overlap (C & D) annotations. Panels A & B
show a vlincRNA potentially produced by bi-directional transcription from a promoter upstream of a known gene. Panels C & D show a
vlincRNA antisense to known genes. Zoom-in on the corresponding promoter regions marked by arrows in A& C are shown in the panels B & D.
The original 580 vlincRNAs[12] (black, non-strand specific) and the ENCODE vlincRNAs (green, strand-specific) are shown. The vlincRNA
designations (vlinc_377 and vlinc_185) refer to Supplementary Table S3 of Kapranov et al[12]. Vlinc_377 (~122 kb, panels A & B) is adjacent to an
annotated gene, ARL15. However, it does not appear to be connected to ARL15, but rather represent a stand-alone independently regulated
unit. Expression of vlinc_377 was restricted to K562, while ARL15 was constitutively expressed and the direction of vlinc_377 transcription was
opposite from ARL15 as shown by the vlincRNA from the ENCODE/CSHL long RNAseq dataset [56] produced with a protocol that reduced
spurious second strand formation [57](Materials and Methods). Consistent with this, a K562-specific promoter element could be identified at the
boundary of vlincRNA_377, upstream of the constitutive promoter controlling the ARL15 expression. Vlinc_185 (C & D) represents an interesting
example of a very long antisense transcript. Due to the original constraint of annotating vlincRNAs as intergenic regions, the vlincRNA bounds
did not extend over the KCNJ16 gene even though the RNAseq signal clearly extends into that gene (C). Furthermore, a spliced EST BE777672
connects vlinc_185 to an intron of KCNJ16 and the 5’ end of this EST corresponds quite well with the end of the RNAseq signal and also with a
K562-specific promoter (C & D). Consistent with this, BE777672 was also isolated from a CML source. The entire length of this vlincRNA would be
~130 kb. Finally, the ENCODE K562 vlincRNA shows the recapitulates the strand and the start site of the previously published vlincRNA. RNAseq
data shows density of informative reads normalized by 10M informative reads. The Y-axis of the alignability track (Materials and Methods) is on
the scale of 0 to 1. Coordinates: hg18.
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LTR-containing sequences from Active promoters asso-
ciated with vlincRNAs can indeed function to initiate tran-
scription, we selected 2 LTR-containing K562-specific
Active promoters and performed reporter gene assays in
two cell lines (K562 and Hep3b) (Figure 4, Materials and
Methods). The sequences used for the assays contained
700-800 bp of upstream genomic flanking regions in addi-
tion to 200-300 bp of LTR (Figure 4, Materials and Meth-
ods). As expected, the sequences functioned as strong
promoter elements, driving expression 200-400 fold above
the empty vector in K562 (Figure 4). They were also active
in Hep3b, albeit at lower levels than in K562 (Figure 4),
suggesting that additional elements and/or trans-acting
factors regulate specific activation of these sequences in
K562 and repression in other cell lines (see below). Endo-
genous LTRs are known to harbor promoter and enhancer
elements, and a number of well characterized LTR-based
promoters of known genes exist[22]. However, to our
knowledge, this is the first description of an association
between LTRs and a very large percentage of the genome
that produces non-coding RNA species with the exception
of a recent paper by Kelley and Rinn that showed associa-
tion of LTR repeats with a different class of non-coding
RNAs (see below) [23].
Interestingly, only LTR-type repeats appear to confer
strong tissue-specific expression patterns on vlincRNAs.
To examine this, we used the original 580 vlincRNAs
for which we had highly quantitative SMS RNAseq data
from total cellular RNA (Table 1). We split the Active
and All promoters according to whether they contained
an LTR, did not contain an LTR but contained another
retroposon, or contained no retroposon repeats, and
categorized the 580 vlincRNAs based on their promoter
association into one of the three above classes. We
defined vlincRNA tissue-specificity, for any tissue in our
previous SMS RNAseq dataset [12], as the ratio of the
highest expresser to the second highest expresser.
The vlincRNAs associated with LTR promoters showed
much higher tissue-specificity than either the non-
repeat or the non-LTR repeat-containing promoters
(Figure 1C). In addition, the vlincRNAs associated with
LTR promoters had higher expression levels than
vlincRNAs associated with other promoters (Figure 1D).
Association between vlincRNAs and retroviral promoters
is a function of transformed or pluripotent state in key
cell lines and primary cells
Using the ENCODE promoter data with normal cells as
well as cell lines at different levels of transformation, we
observed a direct relationship between the number of
Active promoters that overlapped LTRs and the replica-
tive state of the cell. The primary cell lines had the lowest
number of such promoters (397-700), followed by the
immortalized cell line (989), and finally the cancerous
cell lines (1,165-1,199) as shown in Table 2. For each cell
line, we then determined a set of cell-line specific Active
promoters by removing any Active promoter that over-
lapped Active, Weak or Inactive/poised promoters in the
other 8 cell lines. The same trend held true for the cell
line-specific Active promoters: the respective numbers
were: 6-24, 153 and 303-427 (Table 2). However, the
embryonic stem cell line H1-hEsc stood out in this cate-
gory from the other primary cell lines. With 217 specific
Active promoters, H1-hEsc had the highest fraction of
specific Active promoters that overlapped LTRs com-
pared to all other cell lines - 50% (Table 2). This was fol-
lowed by the cancerous cell lines (16.1%-26.7%), the
immortalized cell line (9.7%) and finally the primary cell
lines with an average of 7.3% (highly variable, most likely
due to the low number of promoters that overlapped
LTRs) (Table 2). In summary, while a few LTR’s were
found in Active promoters (both cell-line specific and
Table 2 Distribution of LTRs in Active promoters in malignant, immortalized, primary and embryonic stem cells
Cell Type Total
Promoters
Total
Promoters
that
overlap
LTRs
% of Total
Promoters
that overlap
LTRs
Cell-line
Specific
Promoters
% Cell-
line
Specific
Promoters
Cell-line
Specific
Promoters
that overlap
LTRs
% of Cell line
Specific
Promoters that
overlap LTRs
Number of LTRs
that overlaps cell-
line specific
Promoters
K562 Malignant 15,627 1,199 7.7% 1,599 10.2% 427 26.7% 622
HepG2 Malignant 15,993 1,165 7.3% 1,886 11.8% 303 16.1% 400
GM12878 Immortalized 15,279 989 6.5% 1,613 10.6% 153 9.5% 203
NHLF Primary 14,888 546 3.7% 259 1.7% 15 5.8% 16
HMEC Primary 13,711 535 3.9% 145 1.1% 9 6.2% 12
HSMM Primary 14,335 537 3.7% 305 2.1% 23 7.5% 25
HUVEC Primary 12,319 397 3.2% 102 0.8% 6 5.9% 7
NHEK Primary 14,009 700 5.0% 219 1.6% 24 11.0% 29
H1-hESC Embryonic
Stem
12,477 568 4.6% 453 3.6% 217 47.9% 308
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not) of normal primary cells, far higher numbers were
found in Active promoters of stem cells and cancerous
cells.
We have presented evidence that vlincRNAs associate
with LTR promoters and that malignant and pluripotent
cells recruit LTR promoters much more frequently than
primary cells. We next wanted to close the logical loop
and determine whether cancerous and pluripotent cells
had a higher tendency to express LTR-driven vlincR-
NAs. We compared vlincRNAs and annotated promo-
ters from 6 cell lines common to the ENCODE/CSHL
long RNAseq dataset and ENCODE annotated promo-
ters (Materials and Methods). The malignant/pluripotent
cell lines indeed expressed an order of magnitude higher
absolute number and fraction of vlincRNAs driven by
the LTR promoters than the primary cell lines (Table 3).
The embryonic stem cell line expressed similar numbers
to the cancerous cell lines, while the immortalized cell
lines expressed numbers in between the ES cells and the
primary cells (Table 3).
To validate this intriguing observation in a larger num-
ber of cell types, we investigated expression of vlincRNAs
in 16 cell lines using ENCODE total polyA-RNAseq data:
the 6 ENCODE cell lines in Table 3 and 10 additional cell
lines, including 3 cancerous and 7 primary [24] (Materials
and Methods). In this analysis we compared vlincRNAs
that could be assigned to LTR-containing promoters vs
vlincRNAs assigned to promoters with no LTRs. The ratio
expression of each vlincRNA in cancerous, immortalized
or ES cells compared to the primary cells was calculated
(Materials and Methods). The averages of these ratios for
LTR and nonLTR vlincRNAs are shown in Table 4 (Mate-
rials and Methods). Both, LTR and nonLTR vlincRNAs
showed much higher expression in malignant, immorta-
lized or ESC cells than in primary cells (Table 4).
However, as expected, the upregulation in cancerous,
immortalized and ES cells for the LTR-vlincRNAs was
consistently ~10 fold higher compared to the nonLTR
vlincRNAs (Table 4). The cancerous and ESC lines had
similarly high levels of upregulation relative to primary
cells, while the immortalized cells showed less (Table 4).
This result is again consistent with LTR-driven vlincRNAs
being more highly expressed and more specific to malig-
nant and pluripotent cell types.
Different cell types exhibit diverse patterns of different
types of LTRs activated as vlincRNA promoters
Overall, we detect 8 different types of retroviral elements
enriched in promoters of vlincRNAs in the 6 ENCODE
cell lines (Table 5, Materials and Methods). The primary
cell lines NHEK, HUVEC, and immortalized GM12878
exhibited no significant enrichment of any particular type
of LTR and thus are not shown. We tested enrichment of
retroviral elements present on the sense strand only, and
on either strand, relative to the strand of the correspond-
ing vlincRNAs. In the embryonic stem cells we observed
enrichment of HERVH-int and LTR7 in vlincRNA pro-
moters (Table 5), similar to that previously observed for
lincRNA promoters [23]. However, unexpectedly we also
saw a wide degree of variation between cell types, with
each cell type having a unique pattern of LTR-elements
(Table 5). For example, while the most enriched element
in K562 was LTR12C, it was not enriched in any of the
other 5 cell lines. Interestingly, LTR12 was previously
shown to serve as enhancer and drive expression of long
non-coding RNAs in the beta-globin locus also in K562
cells [25,26]. Similarly, HERVH-int was enriched in
H1-Esc and in K562, but not in any other cell line.
Reciprocally, MER1-int, Harlequin-int and HERVE_a-int
were enriched in vlincRNA promoters in HepG2 cell
line, but not in any other (Table 5).
The “-int” elements denote the internal portions of com-
plete proviruses composed of “-int” regions flanked by
LTRs. While this analysis showed enrichment of only the
internal portions in HepG2, the majority vlincRNA pro-
moters that mapped to the “-int” regions also overlapped
adjacent LTRs. Of the 16 HepG2 vlincRNAs whose pro-
moters mapped to complete proviruses, 15 also overlapped
LTRs. While it is possible that the internal regions of com-
plete proviruses may also contain promoters, at present we
cannot distinguish whether the initiation happens in LTRs
only or in the internal regions. Thus, enrichment of the
Table 3 Enrichment of LTR-driven vlincRNAs in malignant, immortalized, primary and embryonic stem cells
Cell line/
Tissue
Cell Type Number of
vlincRNAs
VlincRNAs Assigned to
LTR* promoters
% Assigned to LTR
promoters
Overlap Expected
by Chance
Fold over
chance
p-value
K562 Malignant 407 119 29.23% 4.5 26.6 7.2E-130
HepG2 Malignant 501 71 14.17% 6.3 11.4 7.9E-51
GM12878 Immortalized 591 47 7.95% 3.5 13.5 7.1E-37
NHEK Primary 248 1 0.40% 1.1 0.9 0.67
HUVEC Primary 340 10 2.94% 1.0 10.0 9.4E-08
H1-hEsc Embryonic
Stem
469 68 14.49% 3.5 19.6 5.4E-64
*Defined as All promoters found in the respective cell line and overlapping an LTR
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‘-int” element in this study primarily refers to enrichment
of the corresponding complete proviruses including their
LTRs.
Some ERV elements like Harlequin-int were enriched
only in the sense polarity to the corresponding vlincRNAs.
Others like HERVH-int in H1-Esc were enriched equally
on the sense or antisense strand relative to the vlincRNAs
(Table 5). The latter is likely at least in part due to bi-
directional transcription that we sometimes observed from
complete proviruses that have both functional LTRs pro-
moters (data not shown). In addition, LTRs are known to
contain bi-directional promoters [27,28].
VlincRNAs represent functional RNAs
There are many ways to determine the functional impor-
tance of a class of RNAs. Syntenic conservation between
species often provides evidence of function, especially in
non-coding RNA with low sequence conservation [29].
To investigate the presence of vlincRNAs in the same
syntenic locations in human and mice, we generated a
vlincRNA dataset from normal mouse lung (Materials
and Methods). In total, 225 mouse vlincRNAs were
found and mapped to the human genome in intergenic
space (Table 1). Similar to the human vlincRNAs, the
mouse vlincRNAs overlap the ENCODE promoters
(Table 1) and in addition, 79/225 mouse vlincRNAs over-
lapped human vlincRNAs (p-value 0.03). This argues for
conservation, and thus, functional importance of this
class of RNAs. In addition to synteny, comparisons to
other independent datasets of known functional impor-
tance can be informative. Analyses show that human
vlincRNAs overlap disease-associated human SNPs found
in multiple GWAS studies (Materials and Methods) to an
extent much greater than that expected by chance: 372/
2,147 vlincRNAs overlapped 576 such SNPs (p-value
0.0134).
Finally, to directly ascertain whether vlincRNAs could
impact cell survival, we conducted siRNA knockdown
experiments with 20 vlincRNAs, 10 K526-specific and 10
found in K562 and other cell lines, and assayed cells for
apoptosis (Materials and Methods). We co-transfected a
plasmid expressing EGFP reporter and assayed % apopto-
tic cells in GFP-positive K562 cells using flow cytometry
(Figure 5A; Additional File 3, Table S3; Additional File 2,
Figures S5-S9). Overall, treatment with siRNAs against
12/20 vlincRNAs resulted in a percentage of apoptotic
cells significantly higher than in the negative siRNA
control (p-value <0.05) (Figure 5A, Additional File 3,
Table S3). siRNA treatments against 9 out of the 12 posi-
tive vlincRNAs resulted in the same or higher effect than
that of siRNA to a known cancer fusion gene, BCR-ABL
(Figure 5A, Additional File 3, Table S3). Notably, the
results also revealed a trend where vlincRNAs common
to different cell lines, i.e. having a low K562-specificity
index, had a higher degree of apoptosis (Figure 5A). The
Spearman correlation between the cell specificity index
(defined as the ratio of K562 levels to maximum levels
in non-K562 tissues and the percentage of apoptotic
cells) was -0.69, indicating that siRNAs against less
K562-specific vlincRNAs had more effect in this study.
Considering that K562-specificity of vlincRNAs is a
totally independent parameter from the siRNA design
and any potential off-target effects, the presence of this
Table 4 Upregulation of vlincRNAs in malignant,
immortalized and embryonic stem cell lines
LTR vlincRNAs non-LTR vlincRNAs
Max* Cancer vs Max Primary 921.2 123.9
Immortalized vs Max Primary 271.5 20.8
ESC vs Max Primary 1,094.4 102.3
*Maximum level in the cancerous or primary cell lines.
Table 5 Enrichment of different LTR elements1 in vlincRNA promoters
K562 HepG2 H1-Esc
Repeat # repeats2 Fold4 (p-value) Repeat # repeats2 Fold4 (p-value) Repeat # repeats2 Fold4 (p-value)
Both Strands3
LTR12C 30 9.48 (1.1E-20) MER61-int 4 22.62 (2.5E-05) HERVH-int 46 9.49 (7.9E-30)
LTR1 8 8.23 (4.6E-06) Harlequin-int 4 9.37 (8.8E-04) LTR7 46 21.66 (1.42E-46)
THE1A 7 10.49 (3.2E-06)
Sense Strand
LTR12C 15 7.48 (2.4E-09) MER61-int 4 39.50 (3.7E-06) HERVH-int 20 5.98 (3.4E-09)
LTR1 7 12.71 (1.2E-06) Harlequin-int 4 14.96 (2.1E-04) LTR7 20 14.02 (5.4E-17)
THE1A 6 16.61 (1.4E-06) HERVE_a-int 2 48.54 (9.2E-04)
1Out of 505 different types of LTR elements listed in RepeatMasker
2Number of the collapsed retroviral elements (see Materials and Methods) in promoters of vlincRNAs
3Non-strand specific analysis. Repeats in both sense and antisense direction relative to the strand of the associated vlincRNAs were counted.
4Fold enrichment of what would be expected by random and the corresponding p-value. Elements with the minimum p-value of 10-4, are given in the ranking
order. To obtain p-value after Bonferroni correction multiple by 505 in non-strand specific analysis or 201 in the sense strand analysis.
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correlation strongly argues against a biological artifact in
these assays. Rather, as one might expect, more constitu-
tively expressed transcripts may have more basic function
and thus a screen based on a basic phenotype, such as
apoptosis would more readily reveal their phenotypes.
More cell-type specific vlincRNAs, like those driven by
LTRs, could have a more specialized function tuned to a
specific cell-type, and thus result in more subtle or spe-
cialized phenotypes not assayed here.
Alternatively, the high level of expression of the K562-
specific vlincRNAs could help explain why some of
them did not show a significant phenotype. The Spear-
man correlation between the density of RNAseq signal
in K562 and the percentage of apoptotic cells after
siRNA treatment was -0.61. Depletion of the more
highly expressed vlincRNAs might have less effect
because sufficient levels could remain for function.
Regardless, 3/10 K562-specific vlincRNAs had statisti-
cally-significant effect in this study and all 3 were driven
by LTR promoters (Figure 5A; Additional File 3, Table
S3 and Additional File 2, Figures S5-S9).
We measured the levels of depletion of vlincRNAs in 4
siRNA treatments that yielded the increased apoptosis
phenotype, and in two that did not, using real-time
RTPCR directly from sorted GFP-positive cells (Figure 5B,
Materials and Methods, Additional File 4, Table S5).
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Figure 5 Results of vlincRNA RNAi inhibition study. Percent of apoptotic GFP-positive cells (Y-axis) is shown for each indicated treatment
(X-axis) for original set of 20 vlincRNAs with 1 siRNA per vlincRNA (A) and for the validation set where 2 additional independent siRNAs per
vlincRNA were designed (C). Depletion of selected vlincRNAs was confirmed using real-time RT-PCR (B). “EGFP only” is transfection with EGFP-
expressing plasmid only, all other designations imply co-transfection of EGFP-expressing plasmid with the indicated siRNA. Treatments
highlighted in yellow are significant at p-value of < 0.05 (Student one-sided t-test). Error bars show standard deviations of 3 independent
transfections (A, C) or RT-PCR reaction (B). Results from the negative control siRNA, positive control siRNA against BCR-ABL and AllStars Hs Cell
Death positive control siRNA blend are also shown. The vlincRNA data is sorted by the K562-specificity index (see text) with the most K562-
specific vlincRNAs on the left (A). Additional details in text and Materials and Methods. The original data is shown in Additional File 3, Table S3.
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As expected, all 4 of the siRNAs that resulted in the
increased apoptosis phenotype showed approximately
2-fold depletion of the corresponding RNAs. Of the two
siRNAs that showed no phenotype, one resulted in deple-
tion of the vlincRNA and one did not (Figure 5B). It is
therefore possible that failure to observe phenotypes with
some siRNAs could be due to inefficient depletion of the
corresponding RNAs, or that a particular vlincRNA is not
involved in the regulation of apoptosis.
To confirm that the observed phenotype was not due to
non-specific events, we have selected two additional siR-
NAs per vlincRNA (Additional File 5, Table S4) for 6
vlincRNAs for which phenotype could be observed, 3 of
which were LTR-driven, and repeated the experiments.
All 12 siRNAs yielded the increased apoptotic phenotype
(Figure 5C, Additional File 3, Table S3). The efficiencies of
additional siRNAs varied, but the general trend remained
the same: the correlation between fractions of apoptotic
cells in the original siRNA experiments and the maximum
of the two new siRNAs was 0.5.
VlincRNAs vs lincRNAs
Overall, there is a low overlap between vlincRNAs and
lincRNAs reported by Kelley and Rinn [23] at the base
pair level: of the 279,818,144 base pairs covered by vlincR-
NAs, only 4,387,800 (1.56%) are covered by exons of
lincRNAs. Median coverage of a vlincRNA that overlaps
exons of a lincRNA is 1.4% of the vlincRNA length. Of the
9,241 lincRNAs, 1,137 (12.3%) overlap vlincRNAs. 1,232/
2,147 (57.4%) of our vlincRNAs have no overlap with any
lincRNA, and the 5’ ends of 82.2% of strand-specific
vlincRNAs were outside of 5 kb of a 5’ end of a lincRNA.
As discussed above, vlincRNA promoters contain different
types of LTR elements and show greater variation between
cell lines than those of lincRNAs. Also, vlincRNAs on
average cover a much larger span of genome than lincR-
NAs (including the introns of the latter): median genomic
length of 83,360 bp for a vlincRNA vs 10,686 bp for a
lincRNA. The construction of vlincRNAs occurred based
on either total cellular RNA or nuclear polyA-RNA, while
lincRNAs were assembled primarily based on polyA+
RNA data. As such, the latter would be heavily enriched in
spliced and polyadenylated non-coding RNAs. On the
other hand, vlincRNAs would represent either polyA+ or
polyA-RNAs.
However, even when vlincRNAs and lincRNAs overlap,
there is still a question of which RNA functions in the
cell, the lincRNA version, the vlincRNA version, or both.
At least three lines of arguments suggest that the long
("vlincRNA-type”) forms have function. First, the known
and characterized macroRNAs function as long unspliced
transcripts. Even though a spliced form for one such
transcript, Air, exists, it makes up a minor form relative
to the unspliced form [14,15]. Second, if unprocessed
forms of lincRNAs are important, one would expect
higher relative abundance of their intronic regions rela-
tive to exons compared to the known protein-coding
genes. To assess this, we calculated the intronic and exo-
nic densities of 781 lincRNAs overlapping K562 vlincR-
NAs and 43,958 UCSC transcripts expressed in that cell
line. Using SMS RNAseq from total K562 RNA, we
found that the median intron/exon ratio for lincRNAs
was indeed significantly higher than for UCSC tran-
scripts: 43.8% vs 12.6%. Finally, we have characterized a
vlincRNA important in cellular senescence and have
shown that its function depends on the unspliced isoform
despite the fact a spliced form has been annotated
(Lazorthes et al, manuscript in preparation).
Discussion
In this study, we show that transcription from very long
stretches of genomic space, often devoid of any known
genes, exists as a common and yet un-recognized property
of human cells. Extrapolating from the set of samples used
here to identify vlincRNAs, this class of transcript could
have much greater numbers and importance than
previously anticipated. In fact, it’s conceivable that by pro-
filing a larger number of cell types, we will find that vlincR-
NAs emanate from most of the genome. Length stands out
as a unique property of these sequences, with some of them
reaching over 1MB (see Additional File 1, Table S1). At
least in some cases, the transcripts are made as one whole
RNA molecule (see Additional File 2, Figure S3; Lazorthes
et. al., manuscript in preparation). As we show here, ele-
ments bearing chromatin marks of bona fide human pro-
moters appear to regulate these vlincRNA regions. Notably,
vlincRNAs encode functional RNA species: depletion of
vlincRNA transcripts in this study has measurable phenoty-
pic effects. In addition, all human samples profiled to date
express vlincRNAs, including normal primary and embryo-
nic stem cells and a normal human tissue, blood. Still, it is
worth noting here that most of our conclusions were
obtained utilizing a limited number of cell lines, and thus
need to be further validated on an expanded set of primary
tissues, both normal and cancerous.
VlincRNAs show statistically-significant association with
SNPs associated with diseases in GWAS studies. In this
respect, the recent work of van Dijk et. al. implicates a 205
kb vlincRNA to HELLP syndrome [30]. This HELLP
vlincRNA completely overlaps one of our vlincRNAs,
however our data suggests a longer and more complex
locus (data not shown, see Additional File 1, Table S1).
Remarkably, that study showed that point mutations
linked to the disease could affect stability of the vlincRNA
and result in downstream functional consequences. These
findings should signal re-evaluation of the results of
GWAS studies where disease-associated variants are often
found outside of known genes.
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All this begs the question of what such huge tran-
scripts could be doing. While some of these vlincRNA
regions could possibly produce spliced protein-coding
transcripts, the long un-spliced versions of these RNAs
would very unlikely code for proteins, especially consid-
ering that, for the most part, they localize to the nucleus
(data not shown). Instead, these RNAs likely participate
in the regulation of gene expression. Indeed, one such
vlincRNA was shown to be critical for maintenance of
the senescent state probably by altering expression of
neighboring genes via epigenetic control of chromatin
state (Lazorthes et. al., manuscript in preparation).
These properties make vlincRNA regions similar to
macroRNAs which were previously associated only with
the regulation of imprinting [14,15]. However, until now,
studies have recognized the presence of only a handful of
such macroRNAs, limited to just six imprinted loci (Igf2r,
Igf2, Kcnq1, Pws/As, Gnas and Dlk1) in the human and/
or mouse genomes [14,15]. Our results suggest that gene
regulation via vlincRNAs and macroRNAs could be a
general theme in human cells. As recently suggested,
these transcripts may function as a type of scaffold to
facilitate regulatory or other processes happening in the
nucleus, [31]. In this respect, the abundance of these
transcripts relative to annotated coding mRNAs is note-
worthy. Either the relative ratio of molecules of the two
types of RNA, or mass of RNA represented by them can
describe their abundance. If these very long molecules
function as complex scaffolds, then the amount of RNA
(mass) is also an important measure of their importance
in a cell. We estimate that in K562 the average molar
ratio of vlincRNA transcripts is 10-20 times lower than
that of protein-coding transcripts, however, the average
absolute mass of vlincRNAs is roughly 5 times higher
than protein-coding transcripts.
Perhaps the most striking result comes from the asso-
ciation of tissue-specific vlincRNAs and LTR-based pro-
moters. While cell-type specific promoters in general
tend to be somewhat enriched in LTR sequences, the
promoters of cell-type specific vlincRNAs demonstrate a
much greater enrichment. The number of LTR-driven
vlincRNAs correlates with certain cellular states. Specific
activation of these very long non-coding transcripts con-
trolled by LTR-based promoters connects stem cells with
cancerous cells, both sharing a high potential for cell
division. In this respect, it’s reminiscent of very recent
studies showing the prominent importance of cancer
stem cells in disease [32-34]. It’s tantalizing to speculate
that these RNAs could participate in the complex
machinery that supports the pluripotent-like properties
of cancerous cells.
Activation of ERVs in some cancers has been observed
previously. These studies have focused mostly on RNAs
and proteins encoded by ERVs [35,36]. However, no
connection has been made to the global importance of
cellular non-coding RNAs, particularly vlincRNAs, dri-
ven by promoters embedded in ERVs or their LTRs in
disease. Here we provide evidence that these cellular
transcripts, rather than the LTRs themselves, constitute
another component mediating the function of ERVs in
pluripotency and malignancy. Exaptation of endogenous
LTRs to serve as primary or alternative promoters of
known genes is a well-documented phenomenon [22].
However, it seems that in most of the well characterized
cases, the LTR promoter either contributes a minor
effect in alternative regulation of the target gene or reca-
pitulates the expression pattern conferred by the pri-
mary promoter [22]. The notable exception to this rule
is specific redirection of expression to placenta [22].
Our results seem to suggest yet another paradigm,
where the endogenous LTRs were exapted to serve as
cell-type specific primary promoters of a class of non-
coding RNAs, and this effect is most pronounced in
pluripotent and malignant cells.
A general theme in the LTR transcriptional activation
observed here is that only a very specific subset of LTRs
function as promoters in any given cell line (Table 2),
arguing against a genome-wide global activation of this
type of sequence. For example, stem cells themselves
could theoretically produce non-functional vlincRNAs
due to their more open chromatin structure [37]. How-
ever, only a tiny fraction (< 0.1%) of all LTR sequences
are active promoters specific to the H1-hEsc cell line,
and only a fraction of those drive vlincRNA expression -
a situation very different from non-specific, genome-
wide activation of transcription. Still this activation is
non-random as indicated by detection of vlincRNAs and
their promoters in different biological replicas of the
same cell line using different techniques. While we have
shown that LTR-promoters of vlincRNAs do indeed
have strong promoter activity in reporter-gene assays,
their DNA sequence alone does not recapitulate the
cell-type specificity found in vivo. Thus, it’s likely that
some other mechanisms such as epigenetic control
define the specificity of LTRs. In fact, the epigenetic sta-
tus of tissue or cell specific LTR promoters has been
shown modulate their activation and repression [38-42].
Furthermore, tumor-specific alterations in DNA methy-
lation of some repeat elements have been reported [43].
Finally, our results connect two genomic features typi-
cally considered “junk DNA”: endogenous viral sequences,
specifically LTRs, and non-coding, intergenic portions of
the genome often with little annotation, the so-called
“gene desert” regions. However, their specific activation in
pluripotent and cancer cells combined with siRNA-based
studies suggest that the conventional wisdom of ignoring
these features should be revisited. Interestingly, enrich-
ment of different LTR elements in vlincRNA promoters
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distinguishes the various cell lines. Even with the small
number of cell lines analyzed here, some clear differences
emerge. The reason behind these differences and their bio-
logical implications offers an interesting direction for
future investigation.
Conclusions
We show two potentially independent dimensions of
functional, endogenous LTRs in the human genome:
selective activation of promoter capabilities of a specific
subset of LTRs in stem and cancerous cells, and associa-
tion of LTR promoters with a specific functional class of
very long non-coding RNAs, vlincRNAs (Figure 6).
These intriguing connections shine a different light on
ignored portions of the genome and highlight the ques-
tion of why specific subsets of LTRs and vlincRNAs
activate in very specific stages of development.
Given the high abundance of vlincRNAs shown in this
paper, we could speculate that much of the dark matter
RNA may take the form of these huge transcripts. While
the scientific community continues to look at the genome
through the prism of short ESTs or lincRNAs scattered
in intergenic space, our data suggests that many of these
transcripts actually belong together in very long tran-
scripts regulated by relatively few promoters. This obser-
vation could be an organizing theme in the biology of
non-coding RNA regulation: very long RNAs that tra-
verse our genome may regulate gene expression in the
nucleus, spiking in early development, and capable of
reactivation in the malignant cellular state.
Materials and methods
Datasets used
I. Publicly-available
1. The 580 K562 - Ewing Sarcoma VlincRNAs: the
coordinates of the vlincRNAs are listed in the Sup-
plementary Table S3 [12].
2. Promoters from 9 human cell lines annotated by
the ENCODE consortium, Broad Institute, MIT and
MGH [5,16,17,44]. The basis of this analysis was
profile of 9 different chromatin marks and input
controls in 9 human cell lines. A Hidden Markov
Model was then used to define 15 different chroma-
tin states based on the different marks, including 3
states that corresponded to Active, Weak and Poised
promoters [17].
3. ENCODE Yale/UC-Davis/Harvard Transcrip-
tion Factor Binding Sites [5,21,45].
4. ENCODE/CSHL long nuclear polyA- and total
polyA-RNAseq dataset [5,6,24,46].
5. LTR repeats were extracted from the RepeatMas-
ker track tables chr[N]_rmsk.txt, where N = 1, ..., 22,
X, Y, M [47,48].
6. UCSC Genes annotations were from the known-
Gene.txt file: HG19 [47] (Last modified 05-Feb-2012)
and HG18 [48] (Last modified 10-May-2009).
7. Disease-associated SNPs from GWAS studies
were downloaded from the corresponding track on
the UCSC Genome browser [49].
8. Alignability track (36mers, Guigo - CGR, Barce-
lona) was downloaded from the UCSC browser [50].
II. Un-published
9. Human blood SMS RNAseq dataset. Prior to rou-
tine angiographic testing for coronary artery disease,
adult volunteers were consented and peripheral blood
was drawn under IRB-approved protocols. All human
studies were conducted in accordance with the princi-
ples of the Helsinki Declaration. All patients provided
informed consent under protocols approved by The
George Washington University Institutional Review
Board (#111051). Blood was drawn into Tempus blood
RNA stabilization tubes and stored at -80°C until
blood RNA was isolated by pelleting cells, disruption,
and column capture of the nucleic acids. Aggressive
DNAse treatment was conducted by treating 10 ug of
total RNA with 10 ul TURBO DNase Buffer and 2 ul
Turbo DNase (Invitrogen AM2238) in a total volume
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Figure 6 Schematic diagram of two-dimensions of endogenous
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of 100 µl at 37°C for 30 minutes followed by DNAse
removal by affinity capture. The resulting RNA was
cleaned using the Qiagen RNAeasy MinElute Cleanup
Kit (Qiagen). Up to 5 ug of the resulting RNA was
then depleted of ribosomal RNA using the RiboZero
rRNA Removal Kit (Epicentre) following the manufac-
turer’s protocol, typically yielding 300-400 ng of
rRNA-depleted RNA. cDNA preparation, tailing and
sequencing using Helicos single-molecule sequencing
technology was performed essentially as described
[12,51]. In total, ~120 million informative reads were
produced. The latter were defined as reads uniquely
aligning to the genome with a minimal normalized
score [12] of 4.3 and filtered for rRNA and chrM
reads.
10. Mouse inflammation RNAseq dataset was pro-
duced by combining ~1 billion informative reads gen-
erated from rRNA-depleted total RNA isolated from
control mouse lung tissue and also treated with lipo-
polysaccharide in different regimes using Helicos sin-
gle molecule sequencing technology. The experimental
details and other aspects of this dataset are described
in St. Laurent et al [52]. The informative reads were
defined as reads uniquely aligning to the genome with
a minimal normalized score [12] of 4.3 and filtered for
rRNA and chrM reads.
The filtered relevant reads from the above datasets
were posted in SRA [SRA:SRP021192].
Construction of vlincRNA regions from different RNAseq
datasets
The ENCODE/CSHL long RNAseq data from nuclear
polyA-RNA subcompartment was downloaded in the
form of “contigs” that represent blocks of overlapping
mapped reads from the pooled biological replicates. We
removed any contigs that overlapped exons or introns of
UCSC Genes. Since the data is strand-specific, all down-
stream analysis was done in a strand-specific fashion -
contigs that overlapped genes on the other strand were
not removed. Contigs separated by 1000 bp or less were
merged and only those merged contigs that were at least
50 kb in length were allowed. Those separated by 5 kb or
less were merged together. The resulting vlincRNAs were
strand-specific.
For construction of vlincRNAs from blood and mouse,
we have first created the read density for each genomic
base in non-strand specific fashion, then removed posi-
tions corresponding to annotated genes. We then applied
to the following consecutive thresholds: density threshold
corresponding to the 80th %-ile of expression, followed
by merging genomic bases separated by no more than
500 bp (blood) or 1000 bp (mouse), followed by selection
of regions of 50 kb or longer. The resulting vlincRNAs
were not strand-specific. For comparison with the human
vlincRNAs, the coordinates of the mouse vlincRNAs were
converted to human coordinates using the LiftOver tool
from the UCSC Genome Browser [53].
Overlap between different datasets
I. Overlap and p-value calculation between the strand-
specific vlincRNAs and promoters.
1) When appropriate, Active, Weak and Poised Pro-
moters from each of the 6 cell lines (K562, GM12878,
HepG2, HUVEC, NHEK and H1-hEsc) were over-
lapped with LTR repeats. In such cases, only promo-
ters that overlap LTR repeats were selected.
2) 10 kb intervals one for each vlincRNA from each of
the 6 cell lines were constructed (+/-5 kb from left
border for the top strand vlincRNAs and +/-5 kb from
right border for the bottom strand vlincRNAs).
3) The number n of 10 kb vlincRNA intervals that
overlap promoters was calculated for each cell line and
each strand.
4) Probability pi that 10 kb interval of i-th vlincRNA
overlap a promoter was calculated by formula
pi =
∣
∣Occupied spacei
∣
∣ /(|Spacei| − V),
for each i = 1, . . . ,N, where
N - number of vlincRNAs in a given dataset and given
strand, |X| is the operator for taking the total length of
the intervals X
Spacei = Genomic space minus Anti space intervals
whose left boundaries for top stranded vlincRNAs (right
boundaries for bottom stranded vlincRNAs) were
extended by length of the given vlincRNA,
Anti space = genomic intervals occupied by UCSC
Known Genes or Encode blacklisted regions* minus
parts that overlap tested vlincRNAs. Gene on the oppo-
site strand was considered intergenic.
V = total length of tested vlincRNAs (V subtracted
from |Spacei| to account for multiple number of
vlincRNAs tested and make upper bound estimation of
p-value).
Occupied spacei = Spacei covered by the tested promo-
ters extended by 5 kb on each side from the corre-
sponding cell line.
*UCSC accessions wgEncodeEH001432 and wgEnco-
deEH000322.
5) The expected number m of intervals overlapping
promoters for each cell line and each strand was cal-
culated as:
m =
∑N
i=1 pi.
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6) P-value as a probability P(ξ ≥ n) was calculated
under assumption that ξ (random variable stand for
number of vlincRNAs that 10 kb interval overlap a
promoter) distributed as binomial B(N,
m
N
).
II. Overlap and p-value calculation between the non-
strand specific vlincRNAs and promoters.
1) For each vlincRNA in a test with size N, two 10
kb intervals were constructed: +/-5 kb from the left
boundary and +/-5 kb from the right boundary.
2) The number of vlincRNAs nwith at least one of
the two 10 kb intervals overlapping a promoter from
the tested class was determined.
3) Probability pi that at least one of two 10 kb intervals
of i-th vlincRNA overlap a promoter was calculated by
formula
pi = 1 −
(
1 − p+i
) (
1 − p−i
)
,
p+i =
∣
∣Occupied space+i
∣
∣ /(|Space+i | − V),
p−i =
∣
∣Occupied space−i
∣
∣ /(|Space−i | − V),
for each i = 1, . . . ,N, where
Space+i = Genomic space minus Anti space intervals
whose left boundaries were extended by length of the
given vlincRNA,
Space−i = Genomic space minus Anti space intervals
whose right boundaries were extended by length of the
given vlincRNA,
Anti space = genomic intervals occupied by UCSC
Known Genes on either strand or Encode blacklisted
regions minus parts that overlap tested vlincRNAs,
V = total length of tested vlincRNAs,
Occupied space+/−i = Space
+/−
i
covered by the tested
promoters extended by 5 kb on each side from the cor-
responding cell line.
4) Expected number of vlincRNAs mwith at least
one of the two 10 kb intervals overlapping a promo-
ter from the tested class was calculated as:
m =
∑N
i=1 pi.
5) P-value as a probability P(ξ ≥ n) was calculated
under assumption that ξ distributed as binomial
B(N,
m
N
).
III. Calculation of p-value for how many vlincRNAs
from set 1 overlap vlincRNAs from set 2.
This procedure is applicable for any genomic interval
data in set 2 including SNP.
1) Probability pi that i-th vlincRNA from set 1 over-
lap any vlincRNA from set 2 was calculated by
formula
pi =
∣
∣Occupied spacei
∣
∣ /(|Spacei| − V),
for each i = 1, . . . ,N, where
N - number of vlincRNAs in set 1,
Spacei = Genomic space minus Anti space intervals
whose both boundaries were extended by half of length
Li/2 of the given vlincRNA,
Anti space = genomic intervals occupied by UCSC
Known Genes or Encode blacklisted regions minus
parts that overlap vlincRNAs from set 1.
V = total length of vlincRNAs from set 1.
Occupied spacei = Spacei covered by the vlincRNAs
from set 2 whose both boundaries were extended by
Li/2.
2) Expected number mof vlincRNAs from set 1 over-
lapping any vlincRNA from set 2 was calculated as:
m =
∑N
i=1 pi.
3) P-value as a probability P(ξ ≥ n), where n is
actual number of vlincRNAs from set 1 overlapping
vlincRNAs from set 2, was calculated under assump-
tion that ξ distributed as binomial B(N,
m
N
).
IV. Non-strand-specific overlap and p-value calcula-
tion between LTRs and vlincRNA promoters.
1) VlincRNA promoters were defined as a join of
Active, Weak and Poised promoters in each cell line
separately (K562, GM12878, HepG2, HUVEC,
NHEK and H1-hEsc) that overlap 10 kb intervals
that center is a 5’ edge of a vlincRNA of the same
cell line.
2) Several LTRs of the same type (LTR7, HERVH-
int,...) were collapsed into one cluster if they were
located in the same promoter or in promoters of the
same vlincRNA. If an LTR overlaps two promoters,
it is split into two LTRs before assigning it to a clus-
ter. LTR clusters are assumed to be distributed in
genome independently relative to each other.
3) The number n of LTR clusters that overlap
vlincRNA promoters was calculated for each cell line
and each LTR type in non-strand-specific manner.
4) Probability p that an LTR cluster overlaps a
vlincRNAs promoter was calculated by formula
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p =
∣
∣Vlincs promoters
∣
∣ /
∣
∣Space promoters
∣
∣ ,
where
|·| - operator for taking of the total length of intervals,
Space promoters - promoters that overlap Space,
Space = Genomic space minus Anti space intervals
whose both boundaries were shrunk by 5 kb,
Anti space = genomic intervals occupied by UCSC
Known Genes plus genomic intervals shorter than
50 kb between UCSC Known Genes minus parts that
overlap vlincRNAs from all 6 cell lines.
5) The number N of LTR clusters overlapping
Space promoters was calculated for each LTR type.
6) P-value as a probability P(ξ ≥ n) was calculated
under assumption that ξ (random variable stand for
number of LTR clusters overlap vlincRNA promo-
ters) distributed as binomial B(N, p).
V. Strand-specific overlap and p-value calculation
between LTRs and vlincRNA promoters.
1) VlincRNA promoters were defined as in IV (1).
2) LTRs on the top strand were collapsed into clus-
ters as in IV (2) and LTRs on the bottom strand
were collapsed into clusters in the same way.
3) The number n+(n−) of top (bottom) strand LTR clus-
ters that overlap top (bottom) strand vlincRNA promo-
ters was calculated for each cell line and each LTR type.
4) Probability p+(p−) that a top (bottom) strand LTR
cluster overlaps a top (bottom) strand vlincRNAs
promoter was calculated by formula
p+ =
∣
∣Vlincs promoters+
∣
∣ /
∣
∣Space promoters+
∣
∣ ,
p− =
∣
∣Vlincs promoters−
∣
∣ /
∣
∣Space promoters−
∣
∣
where
|·| - operator for taking of the total length of intervals,
Vlincs promoters+(−) - promoters of top (bottom)
strand vlincRNAs,
Space promoters+(−) - promoters that overlap Space+(−),
Space promoters+(−) = Genomic space minus
Anti space+(−) intervals whose both boundaries were
shrunk by 5 kb,
Anti space+(−) = genomic intervals occupied by top
(bottom) strand UCSC Known Genes plus genomic
intervals shorter than 50 kb between top (bottom)
strand UCSC Known Genes minus parts that overlap
top (bottom) strand vlincRNAs from all 6 cell lines.
5) The number N+(N−) of top (bottom) strand LTR
clusters overlapping Space promoters+(−) was calcu-
lated for each LTR type.
6) Upper bound of p-value as a probability
P(ξ ≥ n+ + n−) was calculated under assumption
that ξ (random variable stand for number of LTR
clusters overlap vlincRNA promoters) distributed as
binomial B(N+ +N−,max{p+, p−}).
Long-range PCR Assays
RT-PCR
First strand synthesis was performed using Superscript
III (Invitrogen, 18080-051) following the manufacturer’s
protocols with 200 ng Total DNA-free K-562 RNA (Agi-
lent, 540103) as a template. See the Additional File 6,
Table S2 for the gene-specific RT primers used. Each
sample had RNA removed with the addition of 1 µl
RNAse H, incubated at 37 °C for 30 minutes. Subse-
quent PCR was performed using Long Amp Taq PCR
Kit (NEB, E5200S) following the manufacturer’s protocol
on 2.5 µl cDNA in a 25 µl final volume (94 °C 30s, 34x
(94 °C 30 s, 55 °C 30s, 65 °C 5 m), 65 °C 10 m). See the
Additional File 6, Table S2 for the PCR primers used
and the coordinates of the PCR regions. Products were
run on 1% agarose gel.
Genomic PCR
500 ng of genomic DNA from K562 cell line (Pro-
mega, DD201A) was used for PCR using the conditions
above.
Luciferase Reporter Gene Assays
Genomic DNA extracted from cultured cells (Hep3B)
using a kit from Promega was used as template to
amplify the vlincRNA promoter regions detailed below.
Vlinc_185 range_hg18=chr17:65636584-65637598
(V185).
Vlinc_203 range_hg18=chr18:73834656-73835677
(V203)
PGL3-basic-V185(1015bp) was generated by PCR and
subcloned into the PGL3-basic vector at SacI-HindIII
sites, the forward primer was CCGAGCTCTTGAAT
TCCAGGGGTACCAG and the reverse primer was
CCCAAGCTTAGACGGGCTGAGGTCTACAA;
PGL3-basic-V203(1022bp) was generated by PCR and
subcloned into the PGL3-basic vector at KpnI-HindIII
sites, the forward primer was GGGGTACCCTGC-
CAAGGTGAAAGATGCT and the reverse primer was
CCCAAGCTTGCAGGCAAAAAGAGCCTATG;
Transient transfection was performed with Lipofecta-
mine 2000 reagents (Invitrogen) by following the low
serum protocol recommended by the manufacturer.
Hep3b cells were trypsinized 24 hours after transfection,
pooled, divided equally, and cultured in 12-well plates
for luciferase assays. The pRL-CMV (0.1 μg) was
cotransfected to normalize the transfection efficiency.
After 24 hours transfection, suspension K562 cells were
pooled, divided equally, and cultured in 12-well plates
for reporter assays. Luciferase and dual luciferase assays
were performed in 6 replicas for Hep3b and 3 replicas
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for K562 with kits from Promega. Luminescence was
measured in a TD20/20 luminometer (Turner Biosys-
tems), and relative light units (RLU) were standardized
to Renilla luciferase activity expressed from cotrans-
fected pRL-CMV.
Quantitation of vlincRNA expression in 16 ENCODE cell
lines.
The ENCODE/CSHL long RNAseq data from total
polyA-RNA was downloaded in the form of “contigs”
that represent blocks of overlapping mapped reads from
the pooled biological replicates. The 16 cell lines were:
A549, AG04450, BJ, CD20+, GM12878, H1-hESC,
HeLaS3, HepG2, HMEC, HSMM, HUVEC, K562,
MCF7, Monocytes-CD14+, NHEK, NHLF and SK-N-SH
(treated with retinoic acid). More information about the
cell lines can be found on the UCSC browser at the link
for this dataset above. For each vlincRNA, the counts
based on total number of bases covered by reads from
the contig data (column 9 of the BED files) were
obtained and normalized to 20G bases and and 1MBp
of vlincRNA length. Individual vlincRNAs built from the
6 ENCODE cell lines (K562, HepG2, GM12878, H1-hESC,
NHEK and HUVEC) that could be assigned to a promoter
in All category (see Additional File 1, Table S1) were used
in this analysis. These vlincRNAs were further stratified
into 468 and 739 vlincRNAs that could be assigned to a
promoter that overlapped or not an LTR sequence. The
counting was done in a strand-specific fashion and contigs
with very high counts (> 1M) were removed as they could
likely represent artifacts or alignments to highly expressed
sequences such as snRNA or rRNA repeats. Maximal
values for the cancerous and primary cell lines were calcu-
lated (the immortalized and ESC cell lines were repre-
sented only by a single cell line each) for each vlincRNA.
The ratio of maximal values in cancerous cell lines vs that
in primary was then calculated as well as the ratios of
immortalized to max primary and ESC to max primary.
Zero values were replaced by the minimal non-zero
expression value in the dataset. The averages of these
ratios are shown in the Table 4.
VlincRNA inhibition experiments using RNAi
siRNAs against 20 vlincRNAs of the original 580 vlincR-
NAs published in Kapranov et al [12], 1 siRNA per
vlincRNA, were designed using the Whitehead siRNA
design tool [54] and synthesized by Sigma-Aldrich with
dTdT overhangs (sense and antisense). The design was
done to limit possible off-target effects by selecting siR-
NAs with smallest possible number 7mers shared with
conserved regions in 3’ UTRs of known genes [54] (see
Additional File 5, Table S4). In addition one negative con-
trol siRNA, MISSION siRNA universal negative control
#1, (Sigma-Aldrich) and two positive controls were used:
one positive control was the published siRNA against
BCR-ABL fusion mRNA[55] and another was proprietary
“AllStars Hs Cell Death Control siRNA” mix of siRNAs
against house-keeping human genes purchased from Qia-
gen. In addition, for 6 vlincRNAs that showed phenotypes
in the first of the siRNA experiments, we designed two
additional siRNAs per vlincRNA (see Additional File 5,
Table S4).
K562 cells were cultured in RPMI-1640 media with 10%
fetal bovine serum, 100 µg of penicillin/ml, 100 U of strepto-
mycin/ml. The cells were maintained in a humidified 37°C
incubator with 5% CO2. For transfection, 1x10
5 cells were
seeded in a well of 6-well plate with antibiotics-free media
overnight. Then 50 nM siRNA (final concentration) and
1 µg pAAV-CB-EGFP plasmid were complexed with 6 µl of
Lipofectamine 2000 (Invitrogen) in 500 µl of Opti-MEM
media (Invitrogen) according to the manufacturer’s instruc-
tion. The cells were collected 48 hours after transfection and
pelleted by centrifugation at 500g for 5 minutes. The cells
were washed once using 800 µl of labeling buffer (10 mM
HEPES buffer with pH 7.4, 2.5 mM CaCl2 and 140 mM
NaCl). The cells were resuspended in 300 µl of Annexin
V-APC (eBiosciences) labeling buffer and incubated on ice
for 15 min. After washing twice using the labeling buffer,
the cells were stained in 300 µl of 7-AAD (Invitrogen) label-
ing buffer and incubated on ice for 2 minutes. The cells
were washed once before suspended in the labeling buffer
for flow cytometry analysis. For apoptosis analysis, 2,000
EGFP-expressing cells were counted by FACSCalibur flow
cytometer Calibur (BD Biosciences) and the apoptotic cells
were detected as being positive for both EGFP and annexin
V. The statistical analysis were performed by one-tailed
Student’s t-test compared with the negative control siRNA.
Statistically significance was defined as P < 0.05.
Real-time RTPCR on siRNA-treated cells
1x105 of K562 cells were co-transfected with siRNA and
pAAV-CB-EGFP plasmid as mentioned above. The
transfections were duplicated for each siRNA. The cells
were collected at 48 hours after transfection and washed
twice with PBS. For each transfection, 2x104 cells
expressing EGFP were sorted into a 1.5ml-Eppendorf
tube containing 10ul of PBS via Influx™ cell sorter (BD
Biosciences) and the final volume was 50 µl. 5 µl of the
sorted EGFP cells were used for RNA extraction and
reverse transcription using TaqMan® gene expression
cells-to-CT TM kit according to the instruction. Real-
time PCR reactions were duplicated for each RNA sam-
ple. The real-time reaction was performed in 20-µl
system which contained 10 µl of 2x Fast SYBR® Green
Master Mix (Invitrogen), 0.4 µl of each primer (100 µM),
4.2 µl of water and 5 µl of cDNA template. The real time
reactions were run in Mastercycler® Realplex2 (Eppen-
dorf) with the profile 95°C 20 sec, and 45 cycles of 95°C
3 sec and 60°C 30 sec. GAPDH was used as the
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normalization control. All primers are given in Addi-
tional File 4, Table S5.
Additional material
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Additional File 2: Supplementary Figures S1-S9
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